文献速递特殊人群用药

妊娠期生理药代动力学模型:可重复性与外部验证

Physiologically based pharmacokinetic modelling in pregnancy: Model reproducibility and external validation.
PubMed 文献 · Br J Clin Pharmacol · 2021-08-26

本研究旨在重复并重新评估先前发表的倍他米松和丁丙诺啡妊娠期PBPK模型。倍他米松模型在Simcyp V19中成功重复,预测与外部数据AUC比值0.98-1.79;丁丙诺啡模型未能重复,静脉清除率预测为先前报告的70%。模型可重复性和外部数据再评估对学科发展重要。

要点

  • 倍他米松妊娠期PBPK模型在Simcyp V19中可重复,参数估计在先前报告值10%以内。
  • 倍他米松模型外部验证可接受,预测AUC与观察值比值在2倍以内。
  • 丁丙诺啡PBPK模型未能重复,V19预测静脉清除率为V15报告的70%。

核心结论

  • 倍他米松PBPK模型在Simcyp V19中成功重复,并能充分预测妊娠期倍他米松暴露变化。
  • 先前发表的丁丙诺啡PBPK模型未能重复,V19预测静脉清除率为先前报告的70%。
  • PBPK模型的可重复性和外部数据再评估对学科发展重要,发表应包含足够细节以支持重复。

研究设计与样本

  • 基于先前使用Simcyp V17和V15发表的模型,在Simcyp V19中重建倍他米松和丁丙诺啡妊娠期PBPK模型。
  • 通过比较V19预测与先前发表值验证可重复性,参数估计在先前报告值10%以内视为可重复。
  • 使用额外妊娠妇女研究数据重新评估模型,预测AUC和峰浓度在观察值2倍以内视为外部验证可接受。

主要发现

  • 倍他米松模型成功重复,报告(V17)与重现(V19)峰浓度比值0.98-1.04,AUC比值0.95-1.07。
  • 倍他米松模型预测AUC与外部数据比值范围为0.98-1.79。
  • 丁丙诺啡模型不可重复,V19预测静脉清除率为先前报告(均为Simcyp V15)的70%。
  • 新获得的临床数据存在高研究间变异。

关键数值与推荐

  • 模型可重复性标准:参数估计在先前报告值10%以内。
  • 外部验证可接受标准:预测AUC和峰浓度在观察值2倍以内。

临床怎么用

  • 倍他米松妊娠期PBPK模型可用于预测妊娠期倍他米松暴露变化。
  • 使用PBPK模型前应验证其可重复性和外部预测性能。

局限性

  • 新获得的临床数据存在高研究间变异。
  • 丁丙诺啡模型未能重复,原因未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Physiologically based pharmacokinetic (PBPK) models have been previously developed for betamethasone and buprenorphine for pregnant women. The goal of this work was to replicate and reassess these models using data from recently completed studies. METHODS: Betamethasone and buprenorphine PBPK models were developed in Simcyp V19 based on prior publications using V17 and V15. Ability to replicate models was verified by comparing predictions in V19 to those previously published. Once replication was verified, models were reassessed by comparing predictions to observed data from additional studies in pregnant women. Model performance was based upon visual inspection of concentration vs. time profiles, and comparison of pharmacokinetic parameters. Models were deemed reproducible if parameter estimates were within 10% of previously reported values. External validations were considered acceptable if the predicted area under the concentration-time curve (AUC) and peak plasma concentration fell within 2-fold of the observed. RESULTS: The betamethasone model was successfully replicated using Simcyp V19, with ratios of reported (V17) to reproduced (V19) peak plasma concentration of 0.98-1.04 and AUC of 0.95-1.07. The model-predicted AUC ratios ranged from 0.98-1.79 compared to external data. The previously published buprenorphine PBPK model was not reproducible, as we predicted intravenous clearance of 70% that reported previously (both in Simcyp V15). CONCLUSION: While high interstudy variability was observed in the newly available clinical data, the PBPK model sufficiently predicted changes in betamethasone exposure across gestation. Model reproducibility and reassessment with external data are important for the advancement of the discipline. PBPK modelling publications should contain sufficient detail and clarity to enable reproducibility.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Silva LL, Silvola RM, Haas DM, et al. Physiologically based pharmacokinetic modelling in pregnancy: Model reproducibility and external validation. Br J Clin Pharmacol. 2021. PMID: 34337764. doi:10.1111/bcp.15018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。